|
Volumn 26, Issue 4, 2002, Pages 504-509
|
The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects
|
Author keywords
C reactive protein; Chronic systemic inflammation; Leptin; Obesity; PEG OB; Tumor necrosis factor
|
Indexed keywords
C REACTIVE PROTEIN;
LONG ACTING DRUG;
PEGYLATED RECOMBINANT HUMAN LEPTIN;
PLACEBO;
RECOMBINANT LEPTIN;
TUMOR NECROSIS FACTOR ALPHA RECEPTOR;
UNCLASSIFIED DRUG;
ADULT;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG EFFECT;
DRUG MEGADOSE;
FEMALE;
HUMAN;
INFLAMMATION;
LOW CALORY DIET;
MALE;
METABOLISM;
OBESITY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
WEIGHT REDUCTION;
ADOLESCENT;
ADULT;
AGED;
BLOOD GLUCOSE;
BODY MASS INDEX;
BODY WEIGHT;
C-REACTIVE PROTEIN;
DOUBLE-BLIND METHOD;
FEMALE;
HUMANS;
INFLAMMATION;
INSULIN;
INSULIN RESISTANCE;
LEPTIN;
MALE;
MIDDLE AGED;
OBESITY;
PLACEBOS;
PROSPECTIVE STUDIES;
RECEPTORS, TUMOR NECROSIS FACTOR;
WEIGHT LOSS;
|
EID: 85047696643
PISSN: 03070565
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.ijo.0801952 Document Type: Article |
Times cited : (97)
|
References (26)
|